Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-murine TNF antibody refers to a class of monoclonal antibodies specifically designed to bind and neutralize murine tumor necrosis factor (TNF). These antibodies are primarily used as research tools in preclinical mouse models of inflammatory and autoimmune diseases, such as the dextran sulfate sodium (DSS)-induced colitis model. In these settings, they serve as surrogates for human anti-TNF therapeutics (e.g., infliximab, adalimumab) to investigate the role of TNF in disease pathogenesis or to evaluate the efficacy of novel therapeutic candidates in combination or comparison studies. By inhibiting TNF signaling, these antibodies reduce the pro-inflammatory cascade, leading to improvements in clinical scores, histological damage, and mucosal healing in experimental models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-murine TNF antibody.